1. Name and Address of Reporting Person
   Schumacher Laura J
   1 N. WAUKENAG ROAD
   NORTH CHICAGO IL 60064

2. Issuer Name and Ticker or Trading Symbol
   AbbVie Inc. [ ABBV ]

3. Date of Earliest Transaction (Month/Day/Year)
   02/20/2020

4. If Amendment, Date of Original Filed (Month/Day/Year)
   02/24/2020

5. Relationship of Reporting Person(s) to Issuer
   Director, 10% Owner
   Vice Chairman

6. Individual or Joint/Group Filing (Check Applicable Line)
   X Form filed by One Reporting Person
   Form filed by More than One Reporting Person

---

<table>
<thead>
<tr>
<th>Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Title of Security (Instr. 3)</strong></td>
</tr>
<tr>
<td>---------------------------------</td>
</tr>
<tr>
<td>Common Stock, $0.01 par value</td>
</tr>
<tr>
<td>Common Stock, $0.01 par value</td>
</tr>
<tr>
<td>Common Stock, $0.01 par value</td>
</tr>
</tbody>
</table>

---

<table>
<thead>
<tr>
<th>Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Title of Derivative Security (Instr. 3)</strong></td>
</tr>
<tr>
<td>---------------------------------</td>
</tr>
<tr>
<td>Option (right to buy)</td>
</tr>
</tbody>
</table>

---

Explanations of Responses:

1. Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie’s Board of Directors. The shares will be issued to the reporting person on February 28, 2017.

2. Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie’s Board of Directors. The shares will be issued to the reporting person on February 28, 2017.

3. Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie’s Board of Directors. The shares will be issued to the reporting person on February 28, 2018.

4. Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 1, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie’s Board of Directors. The shares will be issued to the reporting person on February 28, 2019.

5. Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 38,189 shares based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie’s Board of Directors. The shares will be issued to the reporting person on February 28, 2020.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
Note: File three copies of this Form, one of which must be manually signed. It is space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

---

Steven L. Scrogham, attorney-in-fact for Laura J. Schumacher
02/24/2020

** Signature of Reporting Person **
*Date*